CHICAGO HIGHLIGHTS 2024 – LUNG ROUNDTABLE DISCUSSION: PALOMA-3
OR
Chair
Dr. Barb Melosky
Panelists
Dr. Rosalyn Juergens
Dr. Peter Ellis
This program has been made possible through unrestricted support from Pfizer
Studies/trials discussed:
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
